The global IgA nephropathy treatment market size was valued at USD 245.8 million in 2022 and is projected to grow at a CAGR of 4.2% during the forecast period of 2023-2031 to reach a value of USD 356.0 million by 2031. The market growth can be attributed to the increasing prevalence of IgA nephropathy, growing awareness about kidney diseases, and advancements in treatment options.
Advancements in medical research have led to the development of new treatment options for IgA nephropathy, including targeted therapies and novel immunosuppressive drugs. Additionally, the growing awareness about kidney diseases and the need for early diagnosis and treatment are also expected to drive market growth.
Efforts to improve access to IgA nephropathy treatment should take into account the unique needs of different regions, as well as the underlying factors that contribute to the development of the disease, such as genetics, environmental factors, and lifestyle choices. By addressing these factors, we can work towards reducing the burden of IgA nephropathy and improving access to effective treatment.
North America is currently the largest market for IgA nephropathy treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of IgA nephropathy, a well-established healthcare infrastructure, and strong investment in medical research and development. In addition, the growing adoption of new treatment options and increased awareness about kidney diseases are further driving the growth of the market in North America.
Europe is also a significant market for IgA nephropathy treatment, with countries such as the UK, Germany, and France leading the way. The region's market growth is driven by factors such as a large population base, increasing awareness of kidney diseases, and government initiatives to address kidney health concerns. Additionally, the region has a well-established healthcare system, which supports the delivery of IgA nephropathy treatment. Asia Pacific is another region that is experiencing significant growth in the IgA nephropathy treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of kidney diseases, and the growing adoption of new treatment options. In addition, government initiatives to address kidney health concerns are helping to drive the growth of the market in the region.
Global IgA Nephropathy Treatment Market: Introduction
IgA nephropathy, also known as Berger's disease, is a kidney disorder caused by the deposition of the immunoglobulin A (IgA) antibody in the kidneys, leading to inflammation and potential kidney damage. The treatment options for IgA nephropathy include medication, dietary changes, and supportive care. The increasing prevalence of IgA nephropathy, coupled with the rising awareness about kidney diseases, is driving the demand for effective treatment options.Advancements in medical research have led to the development of new treatment options for IgA nephropathy, including targeted therapies and novel immunosuppressive drugs. Additionally, the growing awareness about kidney diseases and the need for early diagnosis and treatment are also expected to drive market growth.
IgA Nephropathy Epidemiology
According to the National Kidney Foundation, IgA nephropathy is the most common primary glomerulonephritis worldwide, affecting an estimated 2.5 million people globally. The prevalence of IgA nephropathy varies among countries, with higher rates observed in Asia, particularly in Japan and China. The disease affects both men and women, with a higher prevalence in males.Efforts to improve access to IgA nephropathy treatment should take into account the unique needs of different regions, as well as the underlying factors that contribute to the development of the disease, such as genetics, environmental factors, and lifestyle choices. By addressing these factors, we can work towards reducing the burden of IgA nephropathy and improving access to effective treatment.
IgA Nephropathy Treatment Market Segmentations
The market can be segmented based on diagnosis methods, treatment methods, diseases type, symptoms, age group, route of administration, treatment channel, distribution channel, end-user, and region:Market Breakup by Diagnosis Method
- Blood Test
- Urine Test
- Kidney Biopsy
- Iothalamate Clearance Test
- Others
Market Breakup by Treatment Method
- Corticosteroid Drugs
- Immunosuppressive Drugs
- ACE inhibitors and ARBs
- Others
Market Breakup by Disease Type
- Primary IgA Nephropathy
- Secondary IgA Nephropathy
Market Breakup by Symptoms
- Haematuria
- Proteinuria
- Oedema
- Others
Market Breakup by Age Group
- Adults
- Children
Market Breakup by Route of Administration
Oral
- Tablets/Pills
- Capsules
- Others
Parenteral
- Intravenous
- Intramuscular
- Others
- Others
IgA Nephropathy Treatment Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Distribution Channel of Drugs
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Direct Tender
- Others
Market Breakup by End User
- Hospitals
- Clinics
- Home Healthcare
- Others
Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
IgA Nephropathy Treatment Market Analysis
The market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of IgA nephropathy, rising awareness about kidney diseases, and advancements in treatment options.North America is currently the largest market for IgA nephropathy treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of IgA nephropathy, a well-established healthcare infrastructure, and strong investment in medical research and development. In addition, the growing adoption of new treatment options and increased awareness about kidney diseases are further driving the growth of the market in North America.
Europe is also a significant market for IgA nephropathy treatment, with countries such as the UK, Germany, and France leading the way. The region's market growth is driven by factors such as a large population base, increasing awareness of kidney diseases, and government initiatives to address kidney health concerns. Additionally, the region has a well-established healthcare system, which supports the delivery of IgA nephropathy treatment. Asia Pacific is another region that is experiencing significant growth in the IgA nephropathy treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of kidney diseases, and the growing adoption of new treatment options. In addition, government initiatives to address kidney health concerns are helping to drive the growth of the market in the region.
Key Players in the Global IgA Nephropathy Treatment Market
The report provides a detailed analysis of the key players involved in the IgA nephropathy treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:- Novartis AG
- Calliditas Therapeutics AB
- Chinook Therapeutics Inc
- Travere Therapeutics Inc
- Omeros Corporation
- VIFOR Pharma
- Vera Therapeutics Inc
- Merck KGaA
- Reata Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- Apellis Pharmaceuticals Inc
- Otsuka Pharmaceutical Co. Ltd
Table of Contents
1 Preface
4 IgA Nephropathy Overview
5 Patient Profile
6 Current Scenario Evaluation and Regulatory Framework
7 Challenges and Unmet Needs
8 Global IgA Nephropathy Treatment Market
9 North America IgA Nephropathy Treatment Market
10 Europe IgA Nephropathy Treatment Market
11 Asia Pacific IgA Nephropathy Treatment Market
12 Latin America IgA Nephropathy Treatment Market
13 Middle East and Africa IgA Nephropathy Treatment Market
14 Global IgA Nephropathy Treatment Market Dynamics
15 Supplier Landscape
16 Global IgA Nephropathy Treatment Market - Distribution Model (Additional Insight)
17 Payment Methods (Additional Insight)
Companies Mentioned
- Novartis AG
- Calliditas Therapeutics AB
- Chinook Therapeutics Inc.
- Travere Therapeutics Inc.
- Omeros Corporation
- VIFOR Pharma
- Vera Therapeutics Inc.
- Merck KGaA
- Reata Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc.
- Apellis Pharmaceuticals Inc.
- Otsuka Pharmaceutical Co. Ltd
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 147 |
| Published | April 2023 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value ( USD | $ 256.12 Million |
| Forecasted Market Value ( USD | $ 356 Million |
| Compound Annual Growth Rate | 4.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
Related Reports
IgA Nephropathy (IgAN) - Epidemiology Forecast - 2032
- Report
- 100 Pages
- Global
From
From
Diabetic Nephropathy - Pipeline Insight, 2024
- Clinical Trials
- 60 Pages
- Global
From
From
Diabetic Nephropathy Treatment - Global Strategic Business Report
- Report
- 196 Pages
- Global
From
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
